Drug Profile
ALN AAT
Alternative Names: ALN-AATLatest Information Update: 31 Mar 2022
Price :
$50
*
At a glance
- Originator Alnylam Pharmaceuticals
- Class Small interfering RNA
- Mechanism of Action Alpha 1 antitrypsin inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Alpha 1-antitrypsin deficiency
Most Recent Events
- 15 Mar 2018 Alnylam Pharmaceuticals terminates a phase I/II trial due to observation of low incidence of asymptomatic, transiently elevated liver enzymes in a subset of study subjects in Alpha 1-antitrypsin deficiency in United Kingdom (SC) (NCT02503683)
- 12 Jun 2017 Alnylam Pharmceuticals receives patent allowance for GalNac conjugation technique in USA
- 28 Sep 2016 Pharmacodynamics and safety data from a phase I/II trial in Alpha 1-antitrypsin deficiency released by Alnylam Pharmaceuticals